The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis
- PMID: 32906032
- PMCID: PMC7584725
- DOI: 10.1016/j.semarthrit.2020.06.003
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis
Abstract
Objective: To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF).
Methods: SSc-ILD patients who participated in Scleroderma Lung Study (SLS) II (MMF versus CYC) were included in this study (N = 142). TaqMan Genotyping Assays were used to determine the MUC5B rs35705950 single nucleotide polymorphism. Joint models were created to examine how the presence of this variant affected the course of the forced vital capacity (FVC) over 2 years. Linear regression models were used to investigate the relationship between the presence of this variant and the change in quantitative radiographic fibrosis.
Results: Among 128 participants who were tested for this variant, 18% possessed at least one copy of the MUC5B minor allele. Patients with at least one copy of this allele were similar to those without the allele with respect to age, sex, SSc subtype, ILD disease severity; however, this variant was rare among African Americans (3.7%). The presence of the MUC5B variant did not affect the course of the FVC, nor the change in quantitative radiographic fibrosis, ground glass or ILD scores in either treatment arm.
Conclusion: In the context of a randomized controlled trial for SSc-ILD, the presence of the MUC5B variant did not predict disease severity, nor affect treatment response to MMF or CYC. Future studies are needed to determine whether this variant affects ILD progression in other SSc cohorts and in patients receiving anti-fibrotic therapy.
Keywords: Biomarkers; Cyclophosphamide; Genetics; Interstitial lung disease; Mycophenolate mofetil; Polymorphism; Systemic sclerosis.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interests No non-financial conflicts of interest exist for any of the authors.
Figures
Similar articles
-
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.Arthritis Rheumatol. 2019 Dec;71(12):2059-2067. doi: 10.1002/art.41020. Epub 2019 Nov 1. Arthritis Rheumatol. 2019. PMID: 31233287 Free PMC article.
-
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.Arthritis Res Ther. 2016 Dec 30;18(1):305. doi: 10.1186/s13075-016-1203-y. Arthritis Res Ther. 2016. PMID: 28038680 Free PMC article. Clinical Trial.
-
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23. Arthritis Rheumatol. 2017. PMID: 28376288 Free PMC article.
-
Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.Respir Investig. 2018 Jan;56(1):14-20. doi: 10.1016/j.resinv.2017.11.004. Epub 2017 Dec 6. Respir Investig. 2018. PMID: 29325675 Review.
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article. Review.
Cited by
-
A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.J Clin Lab Anal. 2021 Jun;35(6):e23782. doi: 10.1002/jcla.23782. Epub 2021 May 4. J Clin Lab Anal. 2021. PMID: 33942374 Free PMC article.
References
-
- Wells AU. Interstitial lung disease in systemic sclerosis. Press Med 2014;43:e329–e343. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical